press center press release

EntreMed Inc. (ENMD) President and Chief Executive Officer to Ring the NASDAQ Stock Market Closing Bell

Published

ADVISORY, March 5, 2007 (PRIME NEWSWIRE) --

What: James S. Burns, president and chief executive officer of EntreMed Inc. (ENMD), will preside over the closing bell. The event will mark the beginning of an exciting transitional period for the company. EntreMed is moving forward with multiple mid-stage clinical trials and expects to report clinical results for its two leading oncology drug candidates throughout the year. Where: NASDAQ MarketSite - 4 Times Square - 43rd & Broadway - Broadcast Studio When: Tuesday, March 6, 2007, at 4 p.m. EST Contacts: EntreMed, Inc.: Ginny Dunn Associate Director Corporate Communications & Investor Relations 240.864.2643 NASDAQ MarketSite: Jolene Libretto; 646.441.5220; 347.219.9539 Jolene.Libretto@NASDAQ.com

Feed Information:

The closing bell is available from 3:50 p.m. EST to 4:05 p.m. EST on uplink IA-6 C-band/transponder 17. The downlink frequency is 4040 Vertical; Audio 6.2-6.8 The feed can also be found on Waterfront fiber 1623. If you have any questions, please contact Jolene Libretto at 646.441.5220.

Webcast:

A live Webcast of the NASDAQ Closing Bell will be available at: http://www.nasdaq.com/reference/marketsite_about.stm

Photos:

To obtain a hi-resolution photograph of the Market Close, please go to http://www.nasdaq.com/reference/marketsite_events.stm and click on the market close of your choice.

About EntreMed Inc. (ENMD):

EntreMed Inc. is a clinical-stage pharmaceutical company developing therapeutic candidates primarily for the treatment of cancer and inflammation. Panzem(r) (2-methoxyestradiol or 2ME2), the company's lead drug candidate, is currently in Phase 2 clinical trials for cancer as well as in preclinical development for rheumatoid arthritis. MKC-1, an oral cell cycle regulator, is in Phase 2 studies for cancer. ENMD-1198, a novel tubulin binding agent, is in Phase 1 studies in advanced cancers. EntreMed's goal is to develop and commercialize new compounds based on its expertise in angiogenesis, cell cycle regulation and inflammation -- processes vital to the treatment of cancer and other diseases, such as rheumatoid arthritis. Additional information about EntreMed is available on the company's Web site at www.entremed.com and in various filings with the Securities and Exchange Commission.

In This Story

NDAQ

Nasdaq Press Center

Read the latest press releases, request a press kit, and get in touch with our press team.

learn more